Why Take A Closer Look?
Intelligent Bio Solutions Inc. stands out for several compelling reasons:
Innovative, Patented Technology: Non-invasive, rapid, and highly accurate testing solutions with strong IP protection.
Proven Market Acceptance: Operational in at least 19 countries with a growing base of over 480 customer accounts.
Strong Financial Trajectory: Demonstrated revenue and margin growth, with a scalable, recurring revenue model.
Strategic Global Expansion: Active in high-growth markets and sectors, with multilingual capabilities and key partnerships.
Clear Path to U.S. Market: On track for potential FDA clearance and entry into the world’s largest drug screening market in 2025.
Vision for Broader Diagnostics: Versatile biosensor platform poised for future applications in clinical diagnostics. -----
Five (Nasdaq: INBS) Potential Catalysts To Consider
#1. A Low Float - INBS has a very low float of roughly 1.53Mn shares.
This means volatility potential may be heightened on a daily basis.
#2. An Analyst $12 Target - As of April 17th, Ladenburg Thalmann Co. Inc. was reporting a $12 target on INBS.
From its closing valuation on Friday, that target is suggesting INBS to have over 300% potential upside.
#3. Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified.
Intelligent Bio Solutions announced successful penetration testing supporting its upcoming FDA 510(k) submission, with no major vulnerabilities found and strong validation of its cy-ber-security framework.
The company also introduced enhanced encrypted identification tags and firmware protections to safeguard donor data and ensure test integrity.
Leadership emphasized these milestones as evidence of exceeding regulatory expectations and proactively addressing evolving FDA cy-ber-security guidance.
By reinforcing security early, INBS strengthens its submission prospects and positions its non-invasive testing technology for potential clearance, unlocking significant growth opp's in the large U.S. drug screening market.
#4. Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry.
Intelligent Bio Solutions announced successful manufacturing and shipment of its Intelligent Fingerprinting Drug Screening Readers through its Syrma Johari partnership, marking a major step in scaling production and preparing for U.S. market entry.
The collaboration expands capacity fourfold, meets global quality standards, and supports growing demand across Europe.
The company also doubled in-house test strip production, enhancing vertical integration and innovation.
These efficiencies are expected to reduce costs by over 40% and boost gross margins significantly, positioning INBS for pro-fit-able growth, stronger commercialization, and sustained competitive advantage in global markets ahead.
#5. Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year.
Intelligent Bio Solutions Inc. reported a 48% year-over-year revenue increase for its fiscal second quarter, with reader sales soaring 104%.
First-half 2026 revenue exceeded $2Mn, marking 36% annual growth.
The company’s razor-razorblade sales model—driven by hardware placements and recurring cartridge sales—is fueling sustained pro-fit-ability, with gross pro-fit margins rising to 49%.
Supported by $9.4Mn in new capital, INBS’s strong financial position and expanding installed base underscore its growing market demand, operational efficiency, and progress toward U.S. regulatory clearance and commercial expansion. -----
We've one again kicked off coverage on Intelligent Bio Solutions Inc. (Nasdaq: INBS).
As soon as updates are ready, we'll send them out quickly. Talk soon.
All the best, Dane James Editor Market Pulse Today
Sources: INBS Website INBS Presentation
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 04/20/2026 and ending on 04/20/2026 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid thirty two thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (INBS:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/inbs-aiwop/#details |
No comments:
Post a Comment